Abstract
Introduction: Migraine is a common and disabling neurological disorder. A greater understanding of the pathophysiological mechanisms underlying migraine has led to the availability of specific new drugs targeting calcitonin gene-related peptide (CGRP). The success of the CGRP inhibitors validates research efforts into migraine-specific therapies. Areas covered: There are additional promising therapeutic targets that will be covered in this paper, focusing on the pain phase. They include pituitary adenylate cyclase-activating polypeptide (PACAP), the orexinergic system, the nitric oxide signaling pathway specifically neuronal nitric oxide synthase inhibitors (nNOSi), and metabotropic glutamate receptor 5 (mGluR5). Expert opinion: Based on currently available research; the targets discussed in this paper are all on equal footing with each other in terms of their potential as effective novel migraine therapies. There is a need for more clinical trials to pinpoint which of these potential drug targets will be effective for migraine preventio.
| Original language | English |
|---|---|
| Pages (from-to) | 271-280 |
| Number of pages | 10 |
| Journal | Expert Opinion on Emerging Drugs |
| Volume | 26 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2021 |
Keywords
- CGRP
- metabotropic glutamate receptor 5
- migraine
- neuronal nitric oxide synthase inhibitor
- orexin
- PACAP